Grapefruit-Mavacamten Interaction Leading to Reduced Ejection Fraction Authors: Trevor T Lovell, Jennifer Ogrin, Ahmad Elashery Published: 2026 ABSTRACT AbstractBackgroundMavacamten reduces left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy but carries a risk of exposure-dependent systolic dysfunction due to its narrow therapeutic window.Case SummaryA 57-year-old male with obstructive hypertrophic cardiomyopathy was started on mavacamten resulting in progressive reduction in left ventricular outflow tract gradient with preserved left ventricular ejection fraction (LVEF) over the first several months. Around month 5, he began consuming grapefruit-containing energy drinks daily. After approximately 2 months of exposure, LVEF declined to 45% to 50%. Mavacamten and grapefruit exposure were discontinued, resulting in normalization of LVEF. Rechallenge with mavacamten in the absence of grapefruit did not reproduce systolic dysfunction.DiscussionClinical trials report reversible LVEF reduction with mavacamten; however, real-world pharmacokinetic interactions are less well described. This case demonstrates a probable grapefruit-mediated interaction leading to transient systolic dysfunction.Take-Home MessageUnrecognized dietary cytochrome P450 enzyme inhibition may increase mavacamten exposure and cause reversible systolic dysfunction.Key words: acute heart failure, cardiomyopathy, echocardiography, reduced ejection fraction, systolic heart failure Temporal Relationship Between Mavacamten Therapy, Grapefruit Exposure, and Cardiac Function The clinical timeline demonstrates initial therapeutic response to mavacamten with marked reduction in peak LVOT gradient and preserved LVEF. Around month 5, the patient began daily consumption of grapefruit-containing energy drinks. By month 8, LVEF declined to 45% to 50% while LVOT gradient remained suppressed, prompting discontinuation of mavacamten and grapefruit exposure. LVEF normalized after interruption, with rebound LVOT obstruction. Rechallenge with mavacamten in the absence of grapefruit exposure was associated with stable LVEF and recurrent LVOT gradient reduction. CYP = cytochrome P450; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract. History of Presentation A 57-year-old male with obstructive hypertrophic cardiomyopathy (oHCM) presented for evaluation of persistent exertional dyspnea and intermittent dizziness despite maximally tolerated guideline-directed medical therapy with metoprolol and diltiazem. He denied chest pain, syncope, orthopnea, or lower-extremity edema. His symptoms were progressively limiting his functional capacity. Physical examination demonstrated a systolic murmur at the left sternal border that increased with Valsalva, consistent with dynamic left ventricular outflow tract (LVOT) obstruction. Vital signs were stable without evidence of hypervolemia. Given persistent symptoms despite medical therapy, management options were discussed, including septal reduction therapies (surgical myectomy or alcohol septal ablation) vs initiation of a cardiac myosin inhibitor. After shared decision-making, the patient elected to proceed with mavacamten therapy. Take-Home Message •Unrecognized dietary CYP450 enzyme inhibition may increase mavacamten exposure and cause reversible systolic dysfunction. Unrecognized dietary CYP450 enzyme inhibition may increase mavacamten exposure and cause reversible systolic dysfunction. Past Medical History The patient had a history of known oHCM, coronary artery disease status post percutaneous coronary intervention to the distal right coronary artery in 2021, hypertension, and hyperlipidemia. He had no prior history of heart failure with reduced ejection fraction. He previously demonstrated preserved left ventricular ejection fraction (LVEF) on serial imaging prior to initiation of mavacamten therapy. Investigations Coronary angiography performed prior to mavacamten initiation demonstrated nonobstructive coronary artery disease with a patent right coronary artery stent and no flow-limiting lesions. Baseline transthoracic echocardiography (TTE) demonstrated preserved LVEF of 55% to 60% with severe LVOT obstruction, with a peak gradient of 157 mm Hg. Following initiation of mavacamten 5 mg daily through the Risk Evaluation and Mitigation Strategy (REMS) program, serial TTEs showed the LVOT gradient decreased to 39 mm Hg at month 1 and to 16 mm Hg at month 5. After 5 months, the LVEF remained ≥50%. At month 8, TTE demonstrated new mild systolic dysfunction with LVEF of 45% to 50%, while LVOT gradient remained suppressed at 21 mm Hg. Differential Diagnosis The differential diagnosis for the observed decline in LVEF included progression of hypertrophic cardiomyopathy, medication-related systolic dysfunction from mavacamten, ischemic cardiomyopathy, arrhythmia-mediated cardiomyopathy, and drug or dietary interaction. Given the absence of obstructive coronary disease on left heart catheterization prior to initiation of mavacamten, diffuse rather than regional dysfunction, and temporal association with a new exposure, a pharmacokinetic interaction became the leading consideration. Management Upon identification of a reduced LVEF below 50%, mavacamten was discontinued in accordance with REMS prescribing recommendations. A detailed medication reconciliation and exposure history was then performed to identify potential contributing factors. A review of prescription medications, over-the-counter agents, and herbal supplements revealed no recent changes or additions. In addition, there were no significant changes in renal function or hemodynamic status during this period. However, a more comprehensive evaluation of dietary and beverage habits identified a previously unreported exposure: The patient had begun consuming approximately 1 L per day of energy drinks containing grapefruit, starting during month 5 of mavacamten therapy and prior to the month-5 TTE. Given the known interaction between grapefruit and CYP3A4 metabolism, these beverages were considered a potential contributor to increased mavacamten exposure and were discontinued. No additional pharmacologic changes were made during this period. Outcome and Follow-Up Following discontinuation of mavacamten and grapefruit exposure, a repeat TTE at 1 month demonstrated normalization of LVEF to 55% to 60%, with rebound increase in LVOT gradient to 70 mm Hg. The patient developed progression of his dizziness and exertional dyspnea after the mavacamten was held. After thorough discussions with the manufacturer of mavacamten, the patient was rechallenged with mavacamten 5 mg daily, and subsequent TTEs demonstrated stable LVEF of 55% to 60% with a re-established reduction in LVOT gradient to 26 mm Hg and improvement in his symptoms. The patient has remained clinically stable without recurrence of systolic dysfunction (Figure 1, Table 1). Serial Echocardiographic Doppler Assessment of LVOT Obstruction During Mavacamten Therapy TTE images and continuous-wave Doppler tracings demonstrate changes in LVOT obstruction over the course of therapy. (A) At baseline, severe dynamic LVOT obstruction with peak gradient (Max PG) of 157 mm Hg. (B) After 2 months of mavacamten, peak LVOT gradient decreased to 28 mm Hg. (C) At month 8, during grapefruit-containing beverage exposure, the gradient remained suppressed at 21 mm Hg despite new LVEF decline at 45% to 50%. (D) At month 9, after mavacamten and grapefruit exposure were held, LVOT obstruction rebounded to 70 mm Hg. (E) Following mavacamten rechallenge without grapefruit exposure at month 10, the gradient again decreased and remained controlled at 26 mm Hg by month 12. Abbreviations: TTE = transthoracic echocardiography; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract; PG = pressure gradient; Vmax = peak velocity; Vmean = mean velocity; VTI = velocity-time integral. Table 1Serial Echocardiographic Changes in LVEF and Peak LVOT Gradient During Mavacamten TherapyMonthLVEF (%)Peak LVOT Gradient (mm Hg)NotesBaseline55-60157Pre-mavacamten baseline160-6539Early therapeutic response255-6028Continued LVOT gradient reduction2.560-6522Stable LVEF, improving LVOT gradient550-5516Lower-normal LVEF, new grapefruit exposure845-5021LVEF nadir, mavacamten and grapefruit held955-6070Post-hold, rebound LVOT gradient1055-6026Rechallenge with mavacamten, stable1255-6026Continued stabilityLVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract. Serial Echocardiographic Changes in LVEF and Peak LVOT Gradient During Mavacamten Therapy LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract. Discussion Mavacamten is a selective cardiac myosin inhibitor approved for adults with symptomatic oHCM. By reducing excessive actin-myosin cross-bridge formation, mavacamten decreases myocardial hypercontractility, improves symptoms, and reduces LVOT obstruction.1,2 In EXPLORER-HCM, mavacamten improved functional capacity and symptom burden while reducing postexercise LVOT gradients compared with placebo.1 In VALOR-HCM, mavacamten reduced the proportion of patients who remained eligible for or elected to undergo septal reduction therapy, supporting its role as a disease-specific pharmacologic option for patients with severe symptomatic obstruction despite conventional therapy.2 The same pharmacologic mechanism that makes mavacamten effective also leads to the risk of exposure-related systolic dysfunction. As a negative inotrope, mavacamten requires structured surveillance of LVEF, LVOT gradient, symptoms, and interacting medications.3 Current prescribing information does not recommend initiation or uptitration in patients with LVEF <55% and recommends interruption of therapy if LVEF decreases to <50% at any visit.3 The mavacamten REMS program was established to mitigate the risk of heart failure due to systolic dysfunction through prescriber certification, patient enrollment, pharmacy certification, echocardiographic monitoring, and dose adjustment.4,5 Across clinical trials and real-world surveillance, LVEF reduction below 50% has been consistently recognized as an important safety event, though reported rates vary by population, duration of follow-up, and monitoring framework (Table 2). In EXPLORER-HCM, LVEF <50% occurred in 5.7% of mavacamten-treated patients over 30 weeks.1 Longer-term and higher-risk cohorts have reported higher cumulative rates, including 8.7% in the EXPLORER-LTE cohort of MAVA-LTE over 180 weeks and 13.8% in VALOR-HCM at 128 weeks.2,6 In contrast, REMS program data suggest lower rates in broader real-world practice, with LVEF <50% reported in 4.6% of patients in an early 22-month analysis and 6.7% in a 34-month cumulative analysis.8,9 These differences should be interpreted cautiously because clinical trial cohorts, long-term extensions, and REMS surveillance differ substantially in patient selection, ascertainment, treatment duration, and reporting structure. Table 2Reported LVEF <50% Events During Mavacamten Therapy in Clinical Trials and Real WorldPatient SettingTrial or RegistryDurationMavacamten Cohort SizePatients with LVEF <50%PercentageClinical trialEXPLORER-HCM130 wk12375.7%Clinical trial extensionMAVA-LTE: EXPLORER-LTE Cohort6180 wk231208.7%Clinical trialVALOR-HCM756 wk1081211.1%Clinical trialVALOR-HCM2128 wk1081513.8%Real worldREMS Program822 mo5,5732564.6%Real worldREMS Program934 mo11,0077406.7%Real worldREMS Program, ≥2 years of therapy9≥2 y2,8111906.8%LVEF = left ventricular ejection fraction; REMS = Risk Evaluation and Mitigation Strategy. Reported LVEF <50% Events During Mavacamten Therapy in Clinical Trials and Real World LVEF = left ventricular ejection fraction; REMS = Risk Evaluation and Mitigation Strategy. Mavacamten is metabolized through the cytochrome P450 system, predominantly by CYP2C19 (74%), with additional contribution from CYP3A4 (18%) and CYP2C9 (8%).3,4 Its elimination is prolonged and variable, with a half-life that differs substantially by CYP2C19 metabolic phenotype (8 days in normal metabolizers vs 23 days in poor metabolizers). This prolonged half-life creates the potential for delayed accumulation when metabolic clearance is reduced, particularly when an interacting exposure is sustained rather than intermittent. Although CYP3A4 is not the dominant pathway for mavacamten clearance, inhibition of this pathway may still be clinically relevant in selected patients, especially when CYP2C19 activity is reduced or unknown. Regulatory strategies differ between the United States and Europe. In the United States, mavacamten use is primarily REMS-based and echocardiography-guided, with dose adjustment driven by LVEF, LVOT gradient, symptoms, and interacting medications rather than routine CYP2C19 genotyping or plasma mavacamten concentration monitoring.3,4 In Europe, dosing is more explicitly genotype-informed: CYP2C19 genotyping is recommended before initiation, poor metabolizers are started at 2.5 mg daily with a lower maximum dose, and nonpoor metabolizers are generally started at 5 mg daily with titration based on echocardiographic response and safety parameters.10 Neither regulatory framework currently recommends routine therapeutic drug monitoring with mavacamten plasma concentrations in standard clinical practice. This distinction is relevant to the present case as unrecognized CYP3A4 inhibition may have greater clinical impact when CYP2C19 phenotype is unknown. Grapefruit-containing products are established inhibitors of intestinal CYP3A4 and can increase systemic exposure of several cardiovascular medications.11 The magnitude of interaction is variable and depends on grapefruit product formulation, quantity, frequency of ingestion, intestinal CYP3A4 expression, and the drug's dependence on CYP3A4-mediated first-pass metabolism. The mavacamten-prescribing information document specifically warns patients to avoid grapefruit juice because it may increase the risk of heart failure during treatment, indicating regulatory recognition of this interaction potential.3 Unlike prescribed CYP inhibitors, grapefruit-containing beverages may not be volunteered by patients or captured in pharmacy-based interaction screening, particularly when the exposure is embedded in an energy drink or other nontraditional product. In this case, the patient demonstrated the expected therapeutic response to mavacamten, with substantial reduction in LVOT gradient and initially preserved systolic function. Prior to the time of the month-5 TTE, he began consuming approximately 1 L per day of energy drinks containing grapefruit. After approximately 2 months of daily exposure, LVEF declined to 45% to 50% while the LVOT gradient remained suppressed. This pattern, persistent relief of obstruction with new diffuse systolic dysfunction, is consistent with an exaggerated negative inotropic effect rather than progression of obstructive physiology. A detailed review identified no new prescription medications, over-the-counter agents, herbal supplements, renal dysfunction, or other clear hemodynamic triggers. Mavacamten and grapefruit exposure were discontinued, after which LVEF normalized and LVOT obstruction increased. Subsequent rechallenge with mavacamten in the absence of grapefruit exposure was followed by stable LVEF and recurrent LVOT gradient reduction. This sequence supports a likely pharmacokinetic interaction between grapefruit-containing products and mavacamten, resulting in transient supratherapeutic exposure. This case has important parallels with a recently reported case of cardiogenic shock in a patient receiving mavacamten and clarithromycin.12 Clarithromycin is a strong CYP3A4 inhibitor and would be expected to increase mavacamten exposure through inhibition of a shared metabolic pathway. Medication interaction screening can identify clarithromycin, azole antifungals, antiarrhythmics, and other prescribed CYP inhibitors, but it may fail to detect dietary CYP inhibition unless clinicians specifically ask about grapefruit, grapefruit-containing drinks, and herbal supplements. Therefore, this case extends the interaction concern from conventional drug-drug interactions to the less-visible domain of diet-drug and beverage-drug interactions. Conclusions To the best of our knowledge, this is the first reported case of an interaction between mavacamten and a food- or drink-based exposure. The case emphasizes that safe mavacamten use requires more than protocolized echocardiography and prescription medication review. Clinicians should obtain a targeted exposure history that includes grapefruit products, energy drinks, supplements, herbal products, and nonprescription medications, particularly when LVEF declines after prior stability. In patients receiving mavacamten, small but sustained changes in CYP-mediated metabolism may have clinically meaningful effects because of the drug's prolonged half-life and narrow therapeutic window. This case reinforces the importance of REMS-guided monitoring while highlighting the need for deliberate dietary and beverage counseling as part of routine mavacamten management. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References